Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705431 | 1.00 | CYP1A2 (0.43) | CYP1A2TSHRCYP2C19FABP7FABP5 | |
| SCHEMBL29485540 | 0.80 | FABP7 (0.51) | CYP1A2TSHRCYP2C19FABP7FABP5 | |
| SCHEMBL707704 | 0.77 | CYP1A2 (0.54) | CYP1A2TSHRCYP2C19 | |
| SCHEMBL707399 | 0.77 | CYP1A2 (0.54) | CYP1A2TSHRCYP2C19 | |
| SCHEMBL2893742 | 0.76 | NOTUM (0.41) | TSHRFABP7FABP5SLC6A4SLC6A3 | |
| SCHEMBL2872349 | 0.76 | NOTUM (0.41) | TSHRFABP7FABP5SLC6A4SLC6A3 | |
| SCHEMBL5089511 | 0.76 | NOTUM (0.41) | TSHRFABP7FABP5SLC6A4SLC6A3 | |
| SCHEMBL2887774 | 0.76 | NOTUM (0.41) | TSHRFABP7FABP5SLC6A4SLC6A3 | |
| SCHEMBL4140532 | 0.76 | SLC9A1 (0.50) | SLC6A3 | |
| SCHEMBL19403863 | 0.76 | SLC9A1 (0.50) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124633-B2 | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | CYP1A2 2246/4885TSHR 1200/4885CYP2C19 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.